Rapid diagnostic solutions, developed and brought to market in partnership.
MedMira enables partners to bring rapid diagnostic solutions to market based on its proprietary RVF (Rapid Vertical Flow) Technology™. Built on a flexible platform, assays can be adapted in terms of targets, panel composition, format, and design – from compact single-analyte tests to multiplex configurations with multiple parallel targets. Where required, entirely new assays can be developed from concept through prototyping, validation, and manufacturing. OEM (Original Equipment Manufacturer) and private label models allow partners to define their own product positioning and branding, while relying on established technology, in-house manufacturing, and a clear path to commercialization.
From configurable OEM programs to fully custom assay development
Proven Platform.
Built for Flexibility.
RVF (Rapid Vertical Flow) Technology™ delivers immediate results in a compact, adaptable format, with no waiting time. The system supports both antigen and antibody detection and can be configured from single-target tests to multiplex designs with up to eight targets in parallel – allowing solutions to be tailored to specific applications. This flexibility translates directly into product design, from streamlined single-test devices to multiplex layouts with multiple readouts in one device.
All solutions are backed by in-house manufacturing and global supply capabilities, with production under ISO 13485 and MDSAP certification.
Experience with FDA and Health Canada pathways is reflected in development and manufacturing processes. Support can be provided as needed.
Applications in Practice
The platform is applied across diagnostic and pharmaceutical companies, veterinary health, public health programs, and research environments – wherever rapid, adaptable testing is required. Use cases range from human and veterinary diagnostics to non-clinical applications, supporting programs that need flexibility in format, targets, and deployment.
One example is a feline multiplex test combining HIV, COVID-19, and leukemia targets in a single device – consolidating multiple disease markers into one compact format. Developed and manufactured by MedMira and distributed under partner branding, it demonstrates how the platform can translate specific requirements into a single, deployable solution.
Further updates to follow.
In collaboration with Professor John Alderete, a rapid point-of-care test for Trichomonas vaginalis was developed using MedMira’s RVF Technology™. Using the biomarker ACT::SOE3, the test enables fast and reliable detection of this widespread, often undiagnosed STI. Validated over 12 months, the solution supports earlier diagnosis and improved screening, demonstrating how RVF Technology™ translates research into real-world diagnostics.
Another example is a feline multiplex test combining HIV, COVID-19, and leukemia targets in a single device – consolidating multiple disease markers into one compact format. Developed and manufactured by MedMira and distributed under partner branding, it demonstrates how the platform can translate specific requirements into a single, deployable solution.
For research applications, access is also available through the Miriad® RVF Toolkit.
Explore your options with us
Whether the goal is to configure an OEM solution, develop a new assay, or explore RVF technology in a research context, MedMira welcomes partnership inquiries.